• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

    9.630 -0.270 (-2.73%)
    Streaming Delayed Price Updated: 9:36 AM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about MapLight Therapeutics, Inc. - Common Stock

    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
    Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant... 
    Via MarketBeat
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
    Via The Motley Fool
    News headline image
    MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline. 
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing. 
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.